» Articles » PMID: 35551650

Assessing the Diagnostic Value of a Potential Screening Tool for Detecting Early Interstitial Lung Disease at the Onset of Inflammatory Rheumatic Diseases

Overview
Publisher Biomed Central
Specialty Rheumatology
Date 2022 May 13
PMID 35551650
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Interstitial lung disease (ILD) is a severe pulmonary complication in inflammatory rheumatic diseases (IRD) and associated with significantly increased morbidity and mortality. That is why ILD screening at a very early stage, at the onset of IRD, is essential. The objective of the present study was to evaluate the diagnostic value and utility of a stepwise approach as a potential ILD screening tool in patients with newly diagnosed IRD.

Methods: Consecutively, 167 IRD patients were enrolled. To homogenize the study cohort, an age and gender matching was performed. The case-control study included 126 patients with new onset of IRD (mainly connective tissue diseases [CTD], small vessel vasculitis, and myositis). We applied a stepwise screening algorithm in which all patients underwent pulmonary function testing (PFT) and/or additional chest radiography. If there was at least one abnormal finding, pulmonary high-resolution computed tomography (HRCT) was subsequently performed.

Results: With our stepwise diagnostic approach, we identified 63 IRD patients with ILD (ILD group) and 63 IRD patients without ILD (non-ILD group). A reduced diffusing capacity for carbon monoxide (DLCO) < 80% showed a sensitivity of 83.6% and a specificity of 45.8% compared to chest X-ray with 64.2% and 73.6%, respectively, in detecting ILD. The combination of reduced DLCO and chest X-ray revealed a sensitivity of 95.2% and a specificity of 38.7%. The highest sensitivity (95.2%) and specificity (77.4%) were observed for the combination of reduced DLCO, chest X-ray, and pulmonary HRCT. The most common pulmonary abnormalities on HRCT were ground-glass opacities (GGO; 36.5%), followed by non-specific interstitial pneumonia (NSIP; 31.8%) and usual interstitial pneumonia (UIP; 9.5%).

Conclusions: The combination of reduced DLCO (< 80%), chest X-ray, and pulmonary HRCT yielded the highest sensitivity and specificity in detecting ILD at the onset of IRD. Therefore, this stepwise approach could be a new screening algorithm to identify IRD patients with pulmonary involvement already at the time of the initial IRD diagnosis.

Citing Articles

Proposal of a radiation-free screening protocol for early detection of interstitial lung involvement in seropositive and ACPA-positive rheumatoid arthritis.

Reichenberger F, Popp F, Hoffmann M, Fischinger C, von Wulffen W, Kneidinger N BMC Pulm Med. 2024; 24(1):581.

PMID: 39578822 PMC: 11585148. DOI: 10.1186/s12890-024-03405-y.


Artificial intelligence-based quantification of pulmonary HRCT (AIqpHRCT) for the evaluation of interstitial lung disease in patients with inflammatory rheumatic diseases.

Hoffmann T, Teichgraber U, Lassen-Schmidt B, Renz D, Bruheim L, Kramer M Rheumatol Int. 2024; 44(11):2483-2496.

PMID: 39249141 PMC: 11424669. DOI: 10.1007/s00296-024-05715-0.


Correlation of high-resolution computed tomography and immunological bronchoalveolar lavage in interstitial lung disease at the onset of inflammatory rheumatic diseases: implications for diagnosis and therapeutic strategies.

Hoffmann T, Teichgraber U, Forster M, Oelzner P, Kroegel C, Renz D Arthritis Res Ther. 2024; 26(1):142.

PMID: 39075618 PMC: 11285604. DOI: 10.1186/s13075-024-03371-0.


Overview of Rheumatoid Arthritis-Associated Interstitial Lung Disease and Its Treatment.

Pugashetti J, Lee J Semin Respir Crit Care Med. 2024; 45(3):329-341.

PMID: 38484788 PMC: 11483238. DOI: 10.1055/s-0044-1782218.


[Is JAK inhibition an option in the treatment of interstitial lung disease in rheumatoid arthritis?].

Hoffmann T, Teichgraber U, Lassen-Schmidt B, Kroegel C, Kramer M, Forster M Z Rheumatol. 2023; 83(6):495-499.

PMID: 37847297 PMC: 11322242. DOI: 10.1007/s00393-023-01434-2.


References
1.
Hoffmann T, Oelzner P, Bottcher J, Wolf G, Pfeil A . [Analysis of referral diagnoses to the rheumatology department]. Z Rheumatol. 2019; 79(2):160-167. DOI: 10.1007/s00393-019-0672-1. View

2.
Kerschbaumer A, Sepriano A, Smolen J, van der Heijde D, Dougados M, van Vollenhoven R . Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2020; 79(6):744-759. PMC: 7286044. DOI: 10.1136/annrheumdis-2019-216656. View

3.
Maini M, Adelowo F, Al Saleh J, Al Weshahi Y, Burmester G, Cutolo M . The global challenges and opportunities in the practice of rheumatology: white paper by the World Forum on Rheumatic and Musculoskeletal Diseases. Clin Rheumatol. 2014; 34(5):819-29. PMC: 4408363. DOI: 10.1007/s10067-014-2841-6. View

4.
Newall C, Schinke S, Savage C, Hill S, Harper L . Impairment of lung function, health status and functional capacity in patients with ANCA-associated vasculitis. Rheumatology (Oxford). 2005; 44(5):623-8. DOI: 10.1093/rheumatology/keh548. View

5.
Chua F, Higton A, Colebatch A, OReilly K, Grubnic S, Vlahos I . Idiopathic inflammatory myositis-associated interstitial lung disease: ethnicity differences and lung function trends in a British cohort. Rheumatology (Oxford). 2012; 51(10):1870-6. DOI: 10.1093/rheumatology/kes167. View